Abstract
There is a growing body of evidence that diabetes represents a significant and largely modifiable risk factor for cardiovascular disease (CVD). It is known to markedly increase the risk of CVD—with CVD accounting for 2 of every 3 deaths in patients with diabetes. It is suggested that once patients with diabetes develop clinical coronary disease, they have a grim prognosis. In 2008, the Food and Drug Association mandated the evidence of CV safety in any new diabetic therapy, leading to a multitude of large CV outcome trials to assess CV risk from these medications. However, several of these outcome trials with novel antidiabetic therapies have demonstrated not only safety but a clear and definite CV advantage in patients with type 2 diabetes. In this review, we discuss 2 relatively newer classes of diabetic drugs, sodium glucose cotransport 2 inhibitors and glucagon-like peptide 1 agonists, evaluate their efficacy in improving CV outcomes, and discuss the future of CV prevention with these agents.
Original language | English (US) |
---|---|
Pages (from-to) | 422-427 |
Number of pages | 6 |
Journal | Journal of Cardiovascular Pharmacology and Therapeutics |
Volume | 24 |
Issue number | 5 |
DOIs | |
State | Published - Sep 1 2019 |
Keywords
- GLP-1 agonists
- SGLT-2 inhibitors
- diabetes